This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westby, M.
Right arrow Articles by van der Ryst, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westby, M.
Right arrow Articles by van der Ryst, E.

 Previous Article  |  Next Article 

Journal of Virology, May 2006, p. 4909-4920, Vol. 80, No. 10
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.10.4909-4920.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby,1* Marilyn Lewis,1 Jeannette Whitcomb,2 Mike Youle,3 Anton L. Pozniak,4 Ian T. James,1 Tim M. Jenkins,1 Manos Perros,1 and Elna van der Ryst1

Pfizer Global Research and Development, Sandwich, United Kingdom,1 Monogram Biosciences, South San Francisco, California,2 Royal Free Hospital, London, United Kingdom,3 Chelsea and Westminster Hospital, London, United Kingdom4

Received 26 January 2006/ Accepted 4 March 2006

Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are being developed as the first anti-HIV agents acting on a host cell target. We monitored the coreceptor tropism of circulating virus, screened at baseline for coreceptor tropism, in 64 HIV-1-infected patients who received maraviroc (MVC, UK-427,857) as monotherapy for 10 days. Sixty-two patients harbored CCR5-tropic virus at baseline and had a posttreatment phenotype result. Circulating virus remained CCR5 tropic in 60/62 patients, 51 of whom experienced an HIV RNA reduction from baseline of >1 log10 copies/ml, indicating that CXCR4-using variants were not rapidly selected despite CCR5-specific drug pressure. In two patients, viral load declined during treatment and CXCR4-using virus was detected at day 11. No pretreatment factor predicted the emergence of CXCR4-tropic virus during maraviroc therapy in these two patients. Phylogenetic analysis of envelope (Env) clones from pre- and posttreatment time points indicated that the CXCR4-using variants probably emerged by outgrowth of a pretreatment CXCR4-using reservoir, rather than via coreceptor switch of a CCR5-tropic clone under selection pressure from maraviroc. Phylogenetic analysis was also performed on Env clones from a third patient harboring CXCR4-using virus prior to treatment. This patient was enrolled due to a sample labeling error. Although this patient experienced no overall reduction in viral load in response to treatment, the CCR5-tropic components of the circulating virus did appear to be suppressed while receiving maraviroc as monotherapy. Importantly, in all three patients, circulating virus reverted to predominantly CCR5 tropic following cessation of maraviroc.

* Corresponding author. Mailing address: Pfizer Ltd., PGRD, Sandwich Labs, Kent CT13 9NJ, United Kingdom. Phone: 44 1304-649 876. Fax: 44 1304-651 819. E-mail: mike.westby{at}pfizer.com.

Journal of Virology, May 2006, p. 4909-4920, Vol. 80, No. 10
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.10.4909-4920.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Genebat, M., Ruiz-Mateos, E., Leon, J. A., Gonzalez-Serna, A., Pulido, I., Rivas, I., Ferrando-Martinez, S., Sanchez, B., Munoz-Fernandez, M. A., Leal, M. (2009). Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 64: 845-849 [Abstract] [Full Text]  
  • Murakami, T., Kumakura, S., Yamazaki, T., Tanaka, R., Hamatake, M., Okuma, K., Huang, W., Toma, J., Komano, J., Yanaka, M., Tanaka, Y., Yamamoto, N. (2009). The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100. Antimicrob. Agents Chemother. 53: 2940-2948 [Abstract] [Full Text]  
  • Sundstrom, J. B., Hair, G. A., Ansari, A. A., Secor, W. E., Gilfillan, A. M., Metcalfe, D. D., Kirshenbaum, A. S. (2009). IgE-Fc{epsilon}RI Interactions Determine HIV Coreceptor Usage and Susceptibility to Infection during Ontogeny of Mast Cells. J. Immunol. 182: 6401-6409 [Abstract] [Full Text]  
  • Yost, R., Pasquale, T. R., Sahloff, E. G. (2009). Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 66: 715-726 [Abstract] [Full Text]  
  • Nolan, K. M., Del Prete, G. Q., Jordan, A. P. O., Haggarty, B., Romano, J., Leslie, G. J., Hoxie, J. A. (2009). Characterization of a Human Immunodeficiency Virus Type 1 V3 Deletion Mutation That Confers Resistance to CCR5 Inhibitors and the Ability To Use Aplaviroc-Bound Receptor. J. Virol. 83: 3798-3809 [Abstract] [Full Text]  
  • Anastassopoulou, C. G., Ketas, T. J., Klasse, P. J., Moore, J. P. (2009). Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 106: 5318-5323 [Abstract] [Full Text]  
  • Kitrinos, K. M., Amrine-Madsen, H., Irlbeck, D. M., Word, J. M., Demarest, J. F., on behalf of the CCR100136 Study Team, (2009). Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope. Antimicrob. Agents Chemother. 53: 1124-1131 [Abstract] [Full Text]  
  • Heredia, A., Latinovic, O., Gallo, R. C., Melikyan, G., Reitz, M., Le, N., Redfield, R. R. (2008). Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc. Natl. Acad. Sci. USA 105: 20476-20481 [Abstract] [Full Text]  
  • Schnell, G., Ince, W. L., Swanstrom, R. (2008). Identification and recovery of minor HIV-1 variants using the heteroduplex tracking assay and biotinylated probes. Nucleic Acids Res 36: e146-e146 [Abstract] [Full Text]  
  • Coetzer, M., Nedellec, R., Salkowitz, J., McLaughlin, S., Liu, Y., Heath, L., Mullins, J. I., Mosier, D. E. (2008). Evolution of CCR5 Use before and during Coreceptor Switching. J. Virol. 82: 11758-11766 [Abstract] [Full Text]  
  • Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams, (2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM 359: 1442-1455 [Abstract] [Full Text]  
  • Tsibris, A. M. N., Sagar, M., Gulick, R. M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, F., Leopold, K. E., Coakley, E., Kuritzkes, D. R. (2008). In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. J. Virol. 82: 8210-8214 [Abstract] [Full Text]  
  • Fransen, S., Bridger, G., Whitcomb, J. M., Toma, J., Stawiski, E., Parkin, N., Petropoulos, C. J., Huang, W. (2008). Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition. Antimicrob. Agents Chemother. 52: 2608-2615 [Abstract] [Full Text]  
  • Nakata, H., Steinberg, S. M., Koh, Y., Maeda, K., Takaoka, Y., Tamamura, H., Fujii, N., Mitsuya, H. (2008). Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs. Antimicrob. Agents Chemother. 52: 2111-2119 [Abstract] [Full Text]  
  • Vandekerckhove, L., Verhofstede, C., Vogelaers, D. (2008). Maraviroc: integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother 61: 1187-1190 [Abstract] [Full Text]  
  • Ptak, R. G., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., de Bethune, M.-P., Neyts, J., De Clercq, E., Dumont, J.-M., Scalfaro, P., Besseghir, K., Wenger, R. M., Rosenwirth, B. (2008). Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrob. Agents Chemother. 52: 1302-1317 [Abstract] [Full Text]  
  • Moncunill, G., Armand-Ugon, M., Clotet-Codina, I., Pauls, E., Ballana, E., Llano, A., Romagnoli, B., Vrijbloed, J. W., Gombert, F. O., Clotet, B., De Marco, S., Este, J. A. (2008). Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026. Mol. Pharmacol. 73: 1264-1273 [Abstract] [Full Text]  
  • Nolan, K. M., Jordan, A. P. O., Hoxie, J. A. (2008). Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors. J. Virol. 82: 664-673 [Abstract] [Full Text]  
  • Pastore, C., Nedellec, R., Ramos, A., Hartley, O., Miamidian, J. L., Reeves, J. D., Mosier, D. E. (2007). Conserved Changes in Envelope Function during Human Immunodeficiency Virus Type 1 Coreceptor Switching. J. Virol. 81: 8165-8179 [Abstract] [Full Text]  
  • Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., Perros, M. (2007). Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry. J. Virol. 81: 2359-2371 [Abstract] [Full Text]  
  • Whitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., Petropoulos, C. J. (2007). Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Antimicrob. Agents Chemother. 51: 566-575 [Abstract] [Full Text]  
  • Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antinori, A., Balzarini, J., Perno, C. F. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J. Leukoc. Biol. 80: 1103-1110 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»